Greenwich LifeSciences, Inc. (GLSI)
GLSINASDAQ-CMBiotechnology: Pharmaceutical Preparations
$16.52
+1.35 (+8.90%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $242.48m
- P/E
- –
- EPS, last 4 quarters
- $-1.54
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.78 to $34.10
- Average volume
- 130.8k
- Previous close
- $15.17
Earnings
next estimate $-0.3000Next report Nov 13, 2026
Sep 2025
0.0%
Dec 2025
–
Mar 2026
-18.2%
Jun 2026
+18.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$8.08m | -$2.77m | -$3.77m | -$4.96m |
| Net income | -$8.04m | -$2.75m | -$3.75m | -$4.94m |
News
8 latest- Tuesday Sector Laggards: Biotechnology, Metals & Mining Stocks BNK Invest · Oct 13, 2026
- After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data RTTNews · Aug 20, 2026
- Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes RTTNews · Jul 20, 2026
- Greenwich LifeSciences Becomes Oversold (GLSI)BNK Invest · Jul 17, 2026
- Greenwich Secures European Approval For Use Of Commercially Manufactured GP2 In FLAMINGO-01 RTTNews · Jul 9, 2026
- Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN RTTNews · Jun 5, 2026
- Tuesday Sector Laggards: Application Software, Biotechnology StocksBNK Invest · Jun 2, 2026
- Greenwich Presents Positive Phase 3 FLAMINGO-01 Data For GLSI-100 In Breast Cancer RTTNews · Jun 1, 2026
The company
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- greenwichlifesciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.